VIDEX EC (nda021183)- (125MG,200MG,250MG,400MG)

Generic Name	DIDANOSINE	Innovator	BRISTOL MYERS SQUIBB
Dosage	125MG,200MG,250MG,400MG
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2007-Mar-01	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	VIDEX EC (didanosine) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
125MG	**	**	-	-	-
200MG	**	**	-	-	-
250MG	**	**	-	-	-
400MG	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of VIDEX EC